Hypercholesterolemia Treatment Market Size, Share & Trends Analysis Report, By Treatment (Diagnosis, Medication, Physical Therapy, Others), By Type, By Drug Type, By Distribution Channel, By Route of administration, By End-User, By Region, And by Segment Forecasts, 2023-2031

Report ID : 1457 | Published : 2023-04-18 | Pages: 180 | Format: PDF/EXCEL

The Hypercholesterolemia Treatment Market Size is valued at 27.38 Billion in 2022 and is predicted to reach 36.37 Billion by the year 2031 at a 3.33 % CAGR during the forecast period for 2023-2031.

Hypercholesterolemia Treatment Market

Hypercholesterolemia is a hereditary disorder marked by abnormally high blood cholesterol levels. Hypercholesterolemia, sometimes referred to as dyslipidemia, is a form of hyperlipidemia and hyperlipoproteinemia in the body. Low-density lipoprotein cholesterol (LDL-C), or poor blood cholesterol, can cause cardiovascular problems. A mix of hereditary and environmental causes brings on hypercholesterolemia.

The rising incidence of cardiac disorders and their complications, along with technical improvements in the industry, are factors fueling the expansion of the market for hypercholesterolemia treatment. However, it is anticipated that the high therapy expenses and a shortage of qualified medical personnel will impede the market's expansion. Additionally, it is projected that rising government initiatives in the form of funding, tight rules, and increased awareness in the field of cardiology will spur market expansion.

Additionally, this market will rise during the next ten years due to the significant unmet demand for effective cholesterol treatment. Over the projected period, the worldwide hypercholesterolemia medication market will be driven by an essential rise in awareness of health concerns linked to elevated cholesterol levels as well as an increase in the prevalence of coronary diseases.

Market Segmentation:

The hypercholesterolemia treatment market is segmented on the type, treatment, drug type, route of administration, end-user and distribution channel. Based on type, the market is segmented into type 1, type 2a, type 2b, type 3, type 4, type 5 and others. Based on treatment, the hypercholesterolemia treatment market is segmented into diagnosis, medication, physical therapy and others. Based on drug type, the hypercholesterolemia treatment market is segmented into branded and generics. Based on the route of administration, the hypercholesterolemia treatment market is segmented into oral, parenteral and others. Based on end-user, the hypercholesterolemia treatment market is segmented into hospitals, specialty clinics, home healthcare and others. Based on distribution channels, the hypercholesterolemia treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.

Based On Treatment, The Medication Segment Is Accounted As A Major Contributor To The Hypercholesterolemia Treatment Market.

Based on treatment, the hypercholesterolemia treatment market is segmented into diagnosis, medication, physical therapy and others. The medication category grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time because statins are being used more frequently to treat hypercholesterolemia. The recommended and most well-known pharmacological therapy against hypercholesterolemia is statin therapy. Doctors have long used statin medications to treat hypercholesterolemia, hyperlipoproteinemia, and hypertriglyceridemia as a supplement to diet and exercise.

The Hospital Segment Witnessed Growth At A Rapid Rate.

Based on end-user, the hypercholesterolemia treatment market is segmented into hospitals, specialty clinics, home healthcare and others. The hospital category is anticipated to grow significantly over the forecast period due to the increase of patients seeking treatment for hypercholesterolemia in hospitals. Hypercholesterolemic patients are advised to change their diet and engage in frequent physical activity. Hospitals' advanced infrastructure and qualified medical staff further foster this sector's expansion.

The North American Hypercholesterolemia Treatment Market Holds A Significant Regional Revenue Share.

The North American hypercholesterolemia treatment market is expected to register the highest market share in revenue shortly, linked to escalating medical costs, growing public awareness, and a rise in the prevalence of hypercholesterolemia in the area. The number of people with hypercholesterolemia is increasing, there are more people seeking treatment, and there are more government initiatives to raise awareness. These are other factors driving the market's revenue growth in the area. Additionally, the Asia Pacific is anticipated to expand significantly over the forecast period due to the change in the existence of a sizable population. The market for treating hypercholesterolemia is increasing due to major key players that also influence the Hypercholesterolemia Industry Outlook in this region.


Competitive Landscape

Some major key players in the Hypercholesterolemia Treatment Market:

  • AbbVie, Inc.,
  • Bristol-Myers Squibb Company,
  • Alnylam Pharmaceuticals Inc.,
  • AstraZeneca Plc,
  • Merck & Co., Inc.,
  • Pfizer, Inc.,
  • Amgen, Inc.,
  • Eli Lilly and Company,
  • GlaxoSmithKline plc,
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.


Hypercholesterolemia Treatment Market Report Scope


Report Attribute


Market Size Value In 2022

USD 27.38 Billion

Revenue Forecast In 2031

USD 36.37 Billion

Growth Rate CAGR

CAGR of 3.33 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Billion and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year


Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

Type, Treatment, Drug Type, Distribution Channel, Route of administration, End-User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

AbbVie, Inc., Bristol-Myers Squibb Company, Alnylam Pharmaceuticals Inc., Astrazeneca Plc, Merck & Co., Inc., Pfizer, Inc., Amgen, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG and Regeneron Pharmaceuticals Inc.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Segmentation Of Hypercholesterolemia Treatment Market

By Type-

  • Type 1
  • Type 2a
  • Type 2b
  • Type 3
  • Type 4
  • Type 5
  • Others

Hypercholesterolemia Treatment Market

By Treatment-

  • Diagnosis
  • Medication
  • Physical Therapy
  • Others

By Drug Type-

  • Branded
  • Generics

By Route of Administration-

  • Oral
  • Parenteral
  • Others

By End-User-

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Other

By Distribution Channel-

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Hypercholesterolemia Treatment Market?

Hypercholesterolemia Treatment Market is expected to grow at a 3.33 % CAGR during the forecast period for 2023-2031.

AbbVie, Inc., Bristol-Myers Squibb Company, Alnylam Pharmaceuticals Inc., Astrazeneca Plc, Merck & Co., Inc., Pfizer, Inc., Amgen, Inc., Eli Lilly and

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..